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ABSTRACT Many epidemics of water-borne hepatitis
have occurred throughout India. These were thought to be
epidemics of hepatitis A until 1980, when evidence for an
enterically transmitted non-A, non-B hepatitis was first re-
ported. Subsequently, hepatitis E virus was discovered and
most recent dem of enterically ted non-A, non-B
hepatitis have been attributed to hepatitis E virus infection.
However, only a limited number of cases have been confirmed
by immuno electron microscopy, polymerase chain reaction, or
seroconversion. In the present study we have performed a
retrospective seroepidemiologic study of 17 epidemics of water-
borne hepatitis in India. We have confirmed that 16 of the 17
epidemics were caused at least in part by serologically closely
related hepatitis E viruses. However, one epidemic, in the
Andaman Islands, and possibly a signifnt minrit of cases
in other epidemics, appears to have been caused by a previously
unrecognized hepatitis agent.
Enterically transmitted water-borne hepatitis is recognized
as a major public health problem in many developing coun-
tries (1). The discovery of enterically transmitted non-A,
non-B (ET-NANB) hepatitis, now designated hepatitis E,
resulted from the use of highly sensitive and specific assays
for the diagnosis of hepatitis A and hepatitis B to exclude
these latter two types of hepatitis as the cause of several
epidemics of water-borne hepatitis in India (2, 3). Although
the disease was discovered in 1980 (2, 3) it was not until 1983
that the putative etiologic agent, hepatitis E virus (HEV), was
visualized by immuno electron microscopy (IEM) and IEM
was used to establish the serologic uniqueness of this agent
and to confirm its transmission to humans and nonhuman
primates (4). However, a major impediment to progress in the
study ofHEV was the paucity of virus that could be obtained
from feces of patients and experimentally infected primates
for use as an antigen in serologic tests. In 1990, Reyes et al.
(5) cloned and sequenced part of the HEV genome. Subse-
quently, an enzyme-linked immunosorbent assay (ELISA)
was developed that used recombinant proteins expressed in
Escherichia coli from open reading frames (ORFs) 2 and 3 of
HEV as the source of antigen (6). Recently, Tsarev et al. (7)
developed an ELISA for the detection of IgM and IgG
antibodies to HEV (anti-HEV) that uses a recombinant
protein expressed in insect cells from ORF-2 of HEV as the
source of antigen. This assay is highly sensitive and specific
for the diagnosis of HEV infections and therefore useful for
seroepidemiologic studies (8).
In the past we have investigated 25 epidemics of water-
borne viral hepatitis in India and have demonstrated that
none of these was caused by hepatitis A virus (HAV). They
were therefore classified as ET-NANB hepatitis. In the
present study, we have revisited the question of the etiology
ofET-NANB hepatitis by evaluating patients from 17 ofthese
epidemics for serologic evidence of recent HEV infection.
We have confirmed thatHEV was the cause ofthe 1955 Delhi
epidemic that was integral to the discovery of hepatitis E and
have discovered evidence for another enterically transmitted
hepatitis agent that may be the cause of significant morbidity
in India.
MATERIALS AND METHODS
Epidemics. Seventeen epidemics of hepatitis were included
in the present study (Table 1). All except the Delhi epidemic
were investigated by an experienced team from the National
Institute of Virology, Pune (refs. 2 and 9-12; unpublished
data). All 17 of the epidemics were explosive, water-borne
outbreaks, and fecal contamination ofthe drinking water was
documented in each epidemic. Cases occurred mainly in
young adults, except for the Andaman Islands epidemic, in
which 46% of the cases were in children.
Serolg. Serum samples collected from hepatitis patients
involved in the various epidemics were initially screened for
hepatitis B surface antigen (HBsAg) with a noncommercial
ELISA and for IgM antibodies to HAV (IgM anti-HAV) and
IgM antibodies to hepatitis B core antigen (IgM anti-HBc)
with the HAVAB-M RIA and CORZYME-M tests (Abbott),
respectively. Patients negative for HBsAg, IgM anti-HAV,
and IgM anti-HBc were diagnosed as havingNANB hepatitis
[since patients with acute or chronic hepatitis B virus (HBV)
infection were excluded, we did not test for markers of
hepatitis D virus infection]. Serum from patients in the
Andaman Islands epidemic was also tested for IgM antibod-
ies to leptospira by ELISA (Leptase; Bradsure Biologicals,
Leicestershire, U.K.). After initial screening all the serum
samples were stored at -200C. Randomly selected serum
samples from each epidemic were tested for the presence of
IgM and IgG antibodies to HEV (IgM anti-HEV and IgG
anti-HEV) with an ELISA (8) based on the use of recombi-
nant ORF-2 antigen (13). They were also tested for antibodies
to hepatitis C virus (HCV) with a second-generation ELISA
(Abbott) and confirmed with a supplemental second-
generation recombinant immunoblot assay (RIBA II; Chi-
ron). Samples positive for anti-HCV were excluded from the
study. IgM anti-HEV- and IgG anti-HEV-positive samples
were titrated at 1:100, 1:1000, and 1:10,000 dilutions. All
samples were assayed in duplicate. The negative control
antigen, from insect cells infected with recombinant baculo-
virus lacking the HEV sequence, was purified by following
the protocol for purification of ORF-2 protein. The samples
Abbreviations: ET-NANB, enterically transmitted non-A, non-B;
IEM, immuno electron microscopy; ORF, open reading frame;
GMT, geometric mean titer; HAV, hepatitis A virus; HEV, hepatitis
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Table 1. Water-borne epidemics of hepatitis reexamined in this study
Epidemic This study
No. (%) .
No. of No. of with recent IgM anti-HEV IgG anti-HEV
patients with patients HEV Interval,t reciprocal reciprocal
Location Year hepatitis studied infection* days GMT GMT
Delhi 1955 29,000 28 28 (100) NA* 343 1668
Ahmedabad 1976 2,572 9§ 8 (88.9) 41.9 ± 33.8 2063 4500
Kolhapur 1981 1,169 12§ 10 (83.3) 24.5 ± 18 1122 3870
Ahmedabad 1982 1,072 17 10 (58.8) - 23.2 ± 17.4 200 1000
Ahmedabad 1984 118 22 20 (90.9) 12.1 ± 5.1 1122 1000
Baroda 1984 3,005 16 15 (93.8) 10.0 ± 5.1 1540 1585
Surat 1985 1,395 17 13 (76.5) 18.7 ± 10.1 1000 3162
Ahmedabad 1986 1,015 18 14 (77.8) 15.3 ± 8.2 811 866
Ahmedabad 1987 2,215 33 23 (69.7) 16.9 ± 12.4 1105 848
Andaman Islands 1987 307 75 0 (0) 27.1 ± 11.4 1 1
Khadakwasla 1989 276 19 13 (68.4) 11.5 ± 4.6 2154 1000
Akluj 1990 139 20 18 (90) 12.3 ± 7.1 618 2254
Beed 1990 >3,000 28 26 (92.9) 17.9 ± 10.7 1905 1390
Rewa 1990 517 27 23 (85.2) 33.0 ± 21.6 257 2254
Bijapur 1990 132 17 17 (100) 18.1 ± 7.2 582 1000
Kolhapur 1991 1,442 21 19 (90.5) 12.9 ± 4.7 1274 891
Karad 1993 2,427 27 27 (100) 10.5 ± 5.3 1978 1817
GMT, geometric mean titer.
*Positive for IgM anti-HEV or high titer (21:1000) of IgG anti-HEV.
tInterval between onset of clinical symptoms and collection of serum sample (mean ± SD).
tNot available.
§Paired sera were tested.
positive for IgM or IgG anti-HEV were tested with this
control antigen in ELISA; none was reactive, demonstrating
that the ELISA was specific for anti-HEV.
Stool Samples. Stool samples were collected during the
early acute phase of the disease from NANB patients in-
volved in the epidemics at Ahmedabad (1976, 1984, and
1987), Kolhapur (1981 and 1991), and Akluj (1990) and were
stored at -70°C.
PCR. Stool samples were tested in nested reverse tran-
scription-PCRs as described (14, 15). Sequencing and com-
puter analyses were as described (15).
Statistics. The x2 test for significance was employed.
GMTs were calculated by using an arbitrary titer of 1:1 for
the negative sera.
RESULTS
Fig. 1 depicts the geographic locations of the 17 epidemics
and the year each occurred. The epidemics occurred in
urban, rural, and insular (Andaman) settings. The city of
Ahmedabad experienced water-borne epidemics in 1976,
1982, 1984, 1986, and 1987. The city ofKolhapur experienced
epidemics in 1981 and 1991. Different parts of the two cities
were affected in the different epidemics and the patients in
each epidemic reported they had not had clinical hepatitis
during the previous epidemic(s). Serological studies con-
ducted during the investigation of these 17 epidemics indi-
cated a NANB etiology (refs. 2 and 9-12; unpublished data).
We used PCR specific forHEV to analyze a limited number
of fecal samples collected from patients during six of the
epidemics and were able to detect HEV genomes in seven
samples and to amplify the ORF-3 region from three of the
seven. By employing primers covering the entire ORF-3
region, we showed that there were no deletions in ORF-3
compared with the Burmese strain (16) in the three strains we
studied, in contrast to a previous report of a 246-bp deletion
in ORF-3 of Indian strains (17). Sequences were obtained for
isolates ofHEV from three of the above epidemics (Ahmed-
abad 1976 and 1984; Akluj 1990) as well as from four other
Indian epidemic or sporadic cases. Most of the seven Indian
strains partially sequenced were more closely related to a
Burmese strain (16) (98.5-99.3% nucleotide identity) than to
a Pakistani strain (15) (94.8-95.5% nucleotide identity) and
were very similar to one another (98.9-99.9o nucleotide
identity). One strain (Ahmedabad 1976) was equidistant
between these two reference strains in sequence similarity.
Thus we were able retrospectively to identify HEV as an
etiologic agent in epidemics at Ahmedabad (1976, 1984, and
1987), Kolhapur (1981 and 1991), and Akluj (1990).
Development of a specific and sensitive ELISA for the
detection of IgM and IgG anti-HEV (7) made it possible to
study a much larger number of patients and to compare the
prevalences of HEV infection in the 17 epidemics. The
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FIG. 1. Geographic distribution and year of water-borne hepatitis
epidemics studied.
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frequency with which IgM anti-HEV was detected varied
from epidemic to epidemic and ranged from 0% to 100%1 of
tested sera (Table 1). Although the detection of IgM anti-
HEV proved that HEV was an etiologic agent in most of the
hepatitis epidemics, these discrepant data suggested that
more than one etiologic agent was involved in some of the
epidemics.
The epidemic of water-borne hepatitis in the Andaman
Islands provided the most striking evidence for another
hepatitis agent. Even though the mean interval between onset
of illness and collection of blood from patients in -this epi-
demic was similar to that for the other epidemics studied
(Table 1), none of the 75 patients tested was positive for
anti-HEV.
A detailed account of the Andaman epidemic was pub-
lished previously by Chadha et al. (11). A total of307 hepatitis
cases, including 183 males and 124 females, were reported
(Fig. 2). The diagnosis of viral hepatitis was made by the
investigating team from the National Institute of Virology in
Pune on the basis of clinical signs and symptoms and pres-
ence of bile salts and bile pigments in the urine. The symp-
toms were not consistent with those caused by the common
Gram-negative enteric bacilli, non-typhoid Salmonella, or
the typhoid bacillus. Only low-grade fever of short duration
during the prodrome was reported. The icteric patients
showed no evidence of bradycardia or splenomegaly and all
recovered without the aid of antibiotics. Eighty-five percent
of the patients were icteric, 84%6 had dark urine, 74% were
anorexic, 52% had nausea and vomiting, and 48% had ab-
dominal pain.
Blood samples were collected from 81 patients. Serological
analysis by ELISA demonstrated that 6 patients were suf-
fering from hepatitis A (these were excluded from the present
study), but none of the 81 suffered from acute hepatitis B or
leptospiral infection. Unlike other epidemics of water-borne
NANB hepatitis previously reported in India, 46% of the
patients were children under the age of 15 years.
Five serum samples from the Andaman epidemic previ-
ously had been tested for IgM anti-HEV by Western blot and
two had been found to be weakly positive at a serum dilution
of 1:20 (18). Neither serum was positive by the present
ELISA when tested at a dilution of 1:100, the dilution
routinely employed for this assay (7). To assure that we were
not missing weak anti-HEV responses in these patients, we
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FIG. 2. Epidemic curve of hepatitis cases (no. per week), North
Andaman Island, 1987.
reanalyzed the data with a lower cutoff value for OD (0.2 vs.
0.35). Only two patients were weakly reactive (titer of 1:100)
for IgM anti-HEV only, and two patients were similarly
weakly reactive for IgG anti-HEV only. In addition, we
retested all 75 sera at a 1:20 dilution for IgM and IgG
anti-HEV by ELISA, using the standard cutoff value. Four
additional test sera showed higher OD values, but a compa-
rable number ofnegative control sera also showed similar OD
values. The new samples with the high OD values did not
include the two sera previously found to be positive by
Western blot. Although the Western blot assay correlated
well with the ELISA when samples from other epidemics
were tested, we presume that the previous weak positive
results with the Andaman samples were nonspecific. Since
the vast majority of the Andaman sera were nonreactive in
the ELISA, we conclude that the Andaman epidemic was not
caused by an agent serologically related to HEV.
To ascertain whether the differences in prevalence of
anti-HEV among the epidemics were due to variations in the
interval between the onset of clinical symptoms and collec-
tion of blood samples, the data were analyzed by week after
onset of illness (Fig. 3). During the first week of the clinical
disease, 86% of NANB patients were positive for IgM
anti-HEV (GMT, 1:1129). Similar results were noted through
the third week. Subsequently the percent of sera positive for
IgM anti-HEV declined sharply, as did the GMT. By the end
of week 12 only 21.8% of the patients were IgM anti-HEV
positive and the GMT had decreased to 1:3.7. Meanwhile, the
percent of sera positive for IgG anti-HEV and the GMT,
respectively, for this group of patients rose from 81.4% and
1:405 (week 1) to 86.7% and 1:1817 (week 4). When these data
were compared with the interval between onset of illness and
collection of serum from anti-HEV-negative patients, it was
apparent that the seronegative patients were bled, on aver-
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FIG. 3. (A) Percent ofpatients positive for IgM or IgG anti-HEV,
by week after onset of symptoms. All patients are included. (B) GMT
of IgM and IgG anti-HEV by week after onset of symptoms. All
anti-HEV-positive patients are included.
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age, at a time when they would be expected to be strongly
positive for IgM and/or IgG anti-HEV, had their hepatitis
been hepatitis E.
To determine whether the differences in percent ofpatients
with serologic evidence of HEV infection in different epi-
demics were the result of serologic heterogeneity of HEV
strains, leading to different sensitivities of the ELISA for
different epidemics, we compared the titers ofIgM anti-HEV
for patients from different epidemics. As seen in Fig. 4, the
titers of IgM anti-HEV for patients from epidemics with low
prevalences of anti-HEV positivity were indistinguishable
from those of patients from epidemics with high prevalences
of anti-HEV, indicating that the differences were probably
not due to serologic variation among the epidemic strains of
HEV.
As a further test of whether IgM anti-HEV-negative pa-
tients might actually have represented missed diagnoses of
hepatitis E, we reinvestigated the serologic status of three
patients with acute-phase sera that were negative for IgM
anti-HEV and who had been rebled 41-77 days after onset of
illness. These convalescent sera, from one patient in the
Ahmedabad 1976 outbreak and two patients in the Kolhapur
1981 epidemic, were also negative for both IgM and IgG
anti-HEV, thus confi-ming that these cases of hepatitis were
indeed not etiologically related to known strains of HEV.
Paired sera were not available from other anti-HEV-negative
patients. However, from the absence of both IgM anti-HEV
and high-titered IgG anti-HEV (-1:1000), we conclude that
44 patients from 13 of the remaining 16 epidemics may have
had hepatitis not related to HEV (Table 2). Ten of the 44
patients had low-titered IgG anti-HEV, but we have included
them in the list of possible cases of non-E hepatitis because
patients with low levels of IgG anti-HEV were found in a
previous study to be protected against hepatitis E, probably
by virtue of an infection with HEV at some time in the past
(8). Therefore, these 44 cases of hepatitis, occurring in
conjunction with water-borne epidemics and not serologi-
cally related to any of the five recognized hepatitis viruses,
may have been caused by a previously unrecognized hepatitis
agent.
DISCUSSION
In 1980, Purcell and colleagues (2) reported evidence for a
previously unrecognized hepatitis virus. This conclusion was
based, in part, on a retrospective analysis of sera saved from
the massive epidemic of water-borne hepatitis that occurred
in Delhi in 1955-1956 (1). Similarly, Khuroo (3) provided
evidence that a previously unrecognized hepatitis agent was
the cause of epidemic hepatitis in northern India. Both
studies were based on exclusion of HAV and were made
possible by the development of sensitive and specific sero-
logic tests for HAV, the only water-borne hepatitis virus
recognized at that time.
Subsequent to the identification of hepatitis E virus by
IEM (4), attempts were made to characterize ET-NANB
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FIG. 4. Individual IgM anti-HEV titers of patients from epidem-
ics with a high proportion, intermediate proportion, or low propor-
tion of hepatitis E cases, by week after onset of symptoms. There is
no difference among the epidemics.
epidemics by this technique. Epidemics from India, Nepal,
the former Union of Soviet Socialist Republics, Burma,
Pakistan, Algeria, and Mexico were all shown to be associ-
ated with serologically related viruses. Only Doroshenko et
al. (19) suggested that there was more than one agent causing
epidemic ET-NANB hepatitis, based on the results of IEM.
In the present work, we have used a sensitive and specific
test for anti-HEV to study 17 water-borne epidemics occur-
ring in India during the past 38 years. We confirmed that the
Delhi epidemic was, indeed, caused by HEV and showed that
15 of the other 16 epidemics studied were caused predomi-
nantly or exclusively by HEV, confirming that HEV is an
important human pathogen in India. Although the current
study encompassed epidemics of hepatitis caused by many
different strains of HEV, the magnitudes and temporal rela-
tionships of the IgM and IgG anti-HEV responses were
remarkably similar to those described by Bryan et al. (8) in
the epidemic that occurred in Sargodha, Pakistan, in 1987. In
that epidemic, from which the antigen used for ELISA in the
present study was derived, 92% of 131 cases were identified
as cases of hepatitis E. This suggests that most, if not all,
epidemics of hepatitis E in this region are caused by sero-
logically closely related strains ofHEV. Similarly, in a study
of three epidemics ofNANB hepatitis in villages in Somalia,
Mushahwar et al. (20) noted that 77.8-94% of patients were
suffering from recent HEV infection. Although the expres-
sion systems were different in the two studies, the results
obtained were remarkably similar (20).
However, while underlining the importance ofHEV infec-
tions in India, our data also suggested that some of these
Indian epidemics may have been caused at least in part by a
previously unrecognized agent that is spread by fecal-oral
means. Evidence for such an agent came from several
observations. First, the epidemics studied varied markedly in
the proportion of hepatitis cases that could be ascribed to
HEV. Most compelling was the absence of anti-HEV in
Table 2. Characteristics of patients with water-borne hepatitis in India
Age range S
Type of No. of (mean, median), ex Interval,* No. of
hepatitis patients yr M/F ratio days epidemics
Andaman 75 2-51 (18.5, 17.5) 44/31 (1.4) 27.1 ± 11.4 1
Other non-E 44t 3-60 (25.4, 22) 30/14 (2.1) 16.0 ± 10.5t 13
E 259§ 2-84 (25.4, 23) 197/62 (3.2) 18.5 ± 12.7 15
*Interval between onset of clinical symptoms and collection of serum sample (mean ± SD).
tThirty-four patients negative for IgM and IgG anti-HEV and 10 patients positive only for low-titer IgG
anti-HEV (1:100).
tOnly 8 of the 44 patients were bled during the first week after onset of symptoms.§Excluding the Delhi epidemic, for which data were not available.
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patients from the Andaman epidemic in which there was a
31% attack rate and 307 cases of hepatitis (11). These
differences could not be explained by the interval between
onset of illness and collection ofthe serum sample, the age or
storage conditions of the sera, or the age of the patients. Nor
was there evidence that the differences in prevalence of
anti-HEV among the epidemics studied were caused by
serologic differences among the HEV strains associated with
the epidemics. Sequence analyses of PCR products demon-
strated that viruses recovered from epidemics representing
high and low proportions of hepatitis E cases were all
genetically closely related. A major deletion of 246 bp in the
genome of two Indian strains of HEV has been described
(17). This might affect an ELISA based on ORF-3 but should
not affect the ELISA used here, which was based on ORF-2.
In addition, we were able to show that the reported deletion
was not present in three Indian strains we studied. Although
most Indian strains were more closely related to a Burmese
strain than to the Pakistani strain ofHEV used as the source
of antigen for ELISA in this study, the anti-HEV response to
even the most distantly related (Mexican) strain of HEV, as
well as to the more closely related Burmese strain, can be
detected by this ELISA with a sensitivity equal to that of the
Pakistani strain (ref. 7 and unpublished data). Thus, we do
not believe that the results we describe here can be explained
as an artifact of the assay.
In conclusion, we have provided evidence for the existence
of a sixth human hepatitis agent and the third agent to be
spread by fecal contamination. The Andaman epidemic ap-
pears to have been almost totally caused by an agent other
than HAV or HEV. In India overall, one or more such agents
appear to cause epidemic disease somewhat less frequently
than HEV (70% of the 406 ET-NANB cases studied were
diagnosed as hepatitis E). However, the infection rate could
be higher than the estimate of 30% if the new agent causes
infection at an earlier age than that believed to be typical for
HEV, since many viruses more commonly cause inapparent
infections in the very young. For example, infection with
HAV remains by far the most common hepatitis virus infec-
tion in India but most infections, occurring in the very young,
are clinically inapparent and documented only by serological
means.
As with hepatitis A and hepatitis E previously, the answers
to many questions must await the development of sensitive
and specific assays for the putative agent and antibodies to it.
We presume that it is a virus, but its filterable nature has not
yet been established. However, it is unlikely that such an
agent is geographically restricted to India and evidence (by
serologic exclusion) for its existence elsewhere should be
sought. The data from the Doroshenko et al. (19) study of a
Siberian epidemic, although limited, are consistent with
results obtained in the present study. Further studies will be
required to determine whether the putative new agent is a
second serotype of HEV or an entirely different virus.
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